Incretin-based diabetes medications like GLP-1 receptor agonists consistently reduce postprandial lipemia—the surge of triglycerides and apolipoprotein B48-containing lipoproteins after meals. Kinetic studies reveal these drugs both decrease intestinal lipoprotein output and enhance clearance, while also affecting hepatic apolipoprotein B100 metabolism. The mechanisms involve slowed gastric emptying, altered intestinal fat handling, and modulation of the apolipoprotein C-III/lipoprotein lipase pathway. This lipid modulation represents a previously underappreciated cardiovascular benefit beyond the well-known glucose control and weight loss effects of these blockbuster medications. The finding is particularly relevant given the growing epidemic of postprandial dyslipidemia—elevated after-meal triglycerides that independently predict cardiovascular events. While these medications have already transformed diabetes and obesity treatment, this analysis suggests their lipid effects could contribute meaningfully to their established cardiovascular protection. However, the relative contribution of direct lipid modulation versus indirect benefits from weight loss remains unclear, limiting our ability to quantify this additional protective mechanism.